trending Market Intelligence /marketintelligence/en/news-insights/trending/aIvry0ijzrgyXiJVwkGrwg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Applied Therapeutics plans stock offering to fund drug development

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

Applied Therapeutics plans stock offering to fund drug development

Applied Therapeutics Inc. is planning a common stock offering to raise funds for the development of its drug pipeline.

The New York-based biopharmaceutical company plans to offer 1,750,000 common shares and expects to grant underwriters an overallotment option to purchase up to an additional 262,500 shares.

Funds raised will help the company advance the development of AT-007, AT-001 and AT-003 — each of which is meant to treat complications arising from diabetes.

Goldman Sachs & Co. LLC, Cowen and UBS Investment Bank are joint book-running managers for the offering.